Geisinger, Intermountain Recognized for Precision Medicine Efforts

Geisinger, Intermountain Recognized for Precision Medicine Efforts

Publication date: Mar 20, 2019

March 19, 2019 – Intermountain Healthcare and Geisinger Health System have each received recognition for their work in advancing precision medicine and improving patient care.

READ MORE: Precision Medicine Partnership Aims to Curb Adverse Drug Events -Genomic screening for ARVC offers an opportunity to identify patients at risk for sudden cardiac death prior to the presentation of symptoms,” said Christopher Haggerty, PhD, principal investigator of the study and an assistant professor in Geisinger’s Department of Imaging Science and Innovation.

For someone at risk of sudden cardiac death, this type of ‘precision medicine’ approach could save his or her life, giving us great hope that this research will provide the insights necessary to achieve this goal. “

READ MORE: Precision Medicine Approach Reduces Heart Failure Mortality by 50% -The MyCode Genomic Screening and Counseling team is thrilled to be working with Dr. Haggerty on this innovative and important study,” said Amy Sturm, LGC, a study co-investigator and leader of the MyCode Genomic Screening and Counseling Program, as well as director of Cardiovascular Genomic Counseling at Geisinger.

-Our genetic counseling team works with individuals receiving these ARVC risk results from MyCode, as well as their at-risk family members, and the findings of this study will be key to the type of counseling, anticipatory guidance and preventive recommendations we provide. “

-Precision medicine has opened doors that have allowed us to make a real impact on numerous people in the communities we serve,” said Lincoln Nadauld, MD, chief of precision health for Intermountain Healthcare.

Intermountain’s large biorepository will serve to enhance precision medicine efforts, storing more than three million tissue samples for research and cancer care.

Concepts Keywords
Arrhythmogenic Contributions technology
ARVC Genomics
Biobank MRI
Cardiomyopathy Cardiovascular disease
Cardiovascular Branches of biology
Counseling RTT
Genetic Cardiomyopathy
Genetic Counseling Genomics
Genetic Mutations Genetic counseling
Genetic Variation Precision medicine
Genetics Genomic counseling
Genomics Sudden cardiac death
Intermountain Healthcare Contributions technology
Lincoln
Medicine
MRI
NIH
Opioid Dependence
PhD
Physical Activity
Precision Medicine
Principal Investigator
Scratching
Sudden Cardiac Death
Targeted Treatments
Ventricular

Semantics

Type Source Name
gene UNIPROT CEP55
disease MESH arrhythmogenic right ventricular cardiomyopathy
disease DOID arrhythmogenic right ventricular cardiomyopathy
pathway BSID Arrhythmogenic Right Ventricular Cardiomyopathy
disease MESH heart disease
disease DOID heart disease
disease MESH sudden death
disease MESH Community
disease MESH Adverse Drug Events
disease MESH sudden cardiac death
gene UNIPROT PDC
gene UNIPROT RXFP2
disease MESH multi
gene UNIPROT PTPN5
gene UNIPROT NR4A2
gene UNIPROT ALG3
disease MESH habits
gene UNIPROT CYREN
disease MESH Heart Failure
gene UNIPROT COL25A1
gene UNIPROT OLFM1
drug DRUGBANK Tropicamide
disease MESH lifestyles
disease MESH cancer
disease DOID cancer
gene UNIPROT TBC1D24
gene UNIPROT IMPACT
gene UNIPROT BEST1
gene UNIPROT LARGE1
gene UNIPROT ANP32B
gene UNIPROT TNFSF13

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *